LE 2: Liver Flashcards

1
Q

What percentage of cardiac output does the liver receive?

A) 10%
B) 20%
C) 30%
D) 40%

A

C) 30%

Rationale: The liver receives approximately 30% of the cardiac output.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which vessel supplies oxygenated blood to the liver?

A) Portal vein
B) Hepatic vein
C) Hepatic artery
D) Inferior vena cava

A

C) Hepatic artery

Rationale: The hepatic artery supplies oxygenated blood from the heart to the liver.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which vessel carries nutrient-rich blood from the gut to the liver?

A) Hepatic artery
B) Hepatic vein
C) Portal vein
D) Superior vena cava

A

C) Portal vein

Rationale: The portal vein carries blood directly from the gut to the liver.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which of the following is NOT a function of the liver?

A) Gluconeogenesis
B) Production of insulin
C) Deamination
D) Bilirubin conjugation

A

B) Production of insulin

Rationale: The liver does not produce insulin. Insulin is produced by the pancreas.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which process involves the removal of the amino group from amino acids?

A) Glycolysis
B) Deamination
C) Oxidation
D) Methylation

A

B) Deamination

Rationale: Deamination is the process of removing the amino group from amino acids.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which clotting factor is NOT produced by the liver?

A) II
B) V
C) VIII
D) X

A

C) VIII

Rationale: The liver produces several clotting factors, but factor VIII is not one of them.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which vitamin is NOT stored in the liver?

A) Vitamin A
B) Vitamin C
C) Vitamin D
D) Vitamin K

A

B) Vitamin C

Rationale: The liver stores vitamins A, D, K, B12, and folate, but not vitamin C.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the primary storage form of glucose in the liver?

A) Glucose
B) Fructose
C) Glycogen
D) Galactose

A

C) Glycogen

Rationale: Glycogen is the storage form of glucose in the liver.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which enzyme breaks down certain drugs and neurotransmitters in the liver?

A) Lipase
B) Amylase
C) Plasma cholinesterases
D) Catalase

A

C) Plasma cholinesterases

Rationale: Plasma cholinesterases are enzymes in the liver that break down certain drugs and neurotransmitters.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which process transforms drugs in the liver to make them more water-soluble?

A) Deamination
B) Glycolysis
C) Conjugation
D) Hydrolysis

A

C) Conjugation

Rationale: Conjugation is one of the processes in the liver that transforms drugs to make them more water-soluble.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which mineral is stored in the liver?
A) Calcium
B) Iron
C) Magnesium
D) Potassium

A

B) Iron

Rationale: The liver stores essential minerals like iron and copper.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which of the following is a function of bile acids synthesized by the liver?
A) Blood clotting
B) Digestion and absorption of fats
C) Production of energy
D) Regulation of blood pressure

A

B) Digestion and absorption of fats

Rationale: Bile acids aid in the digestion and absorption of fats.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Which protein synthesized by the liver maintains osmotic balance in the blood?
A) Hemoglobin
B) Collagen
C) Albumin
D) Myoglobin

A

C) Albumin

Rationale: Albumin plays a role in maintaining osmotic balance in the blood.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which process in the liver forms glucose from non-carbohydrate sources?
A) Glycogenesis
B) Glycolysis
C) Gluconeogenesis
D) Glycosylation

A

C) Gluconeogenesis

Rationale: Gluconeogenesis is the formation of glucose from non-carbohydrate sources.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which of the following is NOT a synthetic function of the liver?
A) Production of clotting factors
B) Synthesis of bile acids
C) Conversion of ammonia to urea
D) Synthesis of albumin

A

C) Conversion of ammonia to urea

Rationale: Conversion of ammonia to urea is a metabolic function of the liver, not a synthetic function.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Which clotting factor is produced by the liver and is also known as prothrombin?
A) II
B) V
C) VII
D) X

A

A) II

Rationale: Factor II is also known as prothrombin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Which process in the liver makes bilirubin water-soluble?
A) Oxidation
B) Reduction
C) Conjugation
D) Hydrolysis

A

C) Conjugation

Rationale: Conjugation of bilirubin in the liver makes it water-soluble.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Which of the following is a primary function of the liver in relation to fats?
A) Synthesis of fatty acids
B) Breakdown of triglycerides and cholesterol
C) Production of lipase enzyme
D) Storage of fatty acids

A

B) Breakdown of triglycerides and cholesterol

Rationale: The liver plays a role in the metabolism of triglycerides and cholesterol.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Which vessel drains blood out of the liver?
A) Hepatic artery
B) Hepatic vein
C) Portal vein
D) Superior vena cava

A

B) Hepatic vein

Rationale: The hepatic vein drains blood out of the liver and into the inferior vena cava.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Which of the following substances is transformed from lipid to water-soluble in the liver?
A) Oxygen
B) Carbon dioxide
C) Drugs
D) Water

A

C) Drugs

Rationale: The liver transforms drugs from lipid-soluble to water-soluble forms to aid in their excretion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Which enzyme is responsible for oxidation and reduction in Phase 1 drug metabolism?

A) Hemoglobin
B) Cytochrome P450
C) Myoglobin
D) Lysozyme

A

B) Cytochrome P450
Rationale: Cytochrome P450 performs oxidation and reduction reactions, which are part of Phase 1 drug metabolism.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Where is Cytochrome P450 primarily located?

A) Cytoplasm
B) Mitochondria
C) Cell membrane
D) Nucleus

A

B) Mitochondria
Rationale: CYP enzymes are primarily found in the mitochondria of liver cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What characteristic feature does Cytochrome P450 have?

A) Absorbs light at 450 nm when exposed to oxygen
B) Absorbs light at 450 nm when exposed to carbon monoxide
C) Absorbs light at 500 nm when exposed to carbon dioxide
D) None of the above

A

B) Absorbs light at 450 nm when exposed to carbon monoxide
Rationale: Cytochrome P450 contains a heme pigment that absorbs light at a wavelength of 450 nm when exposed to carbon monoxide.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Which of the following is NOT a major CYP protein in drug metabolism?

A) CYP1A2
B) CYP2C9
C) CYP4A7
D) CYP3A5

A

C) CYP4A7
Rationale: CYP1A2, CYP2C9, CYP2D6, CYP3A4, and CYP3A5 are the major CYP proteins involved in drug metabolism.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Which CYP enzyme metabolizes Codeine?

A) CYP2D6
B) CYP3A4
C) CYP1A2
D) CYP2C9

A

A) CYP2D6
Rationale: Codeine is a substrate of CYP2D6.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Which substance inhibits CYP3A4?

A) Quinidine
B) Methadone
C) Grapefruit juice
D) Lidocaine

A

C) Grapefruit juice
Rationale: Grapefruit juice is an inhibitor of CYP3A4.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What is the prevalence of ultrarapid metabolizers in the African or Ethiopian population?

A) 1-2%
B) 3.4-6.5%
C) 29%
D) 6%

A

Answer: C) 29%
Rationale: The prevalence of ultrarapid metabolizers in the African or Ethiopian population is 29%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Which of the following drugs is a substrate of CYP3A4?

A) Bufuralol
B) Erythromycin
C) Desipramine
D) Codeine

A

Answer: B) Erythromycin
Rationale: Erythromycin is a substrate of CYP3A4.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Which enzyme is inhibited by Fluoxetine?

A) CYP2D6
B) CYP3A4
C) CYP1A2
D) CYP2C9

A

A) CYP2D6
Rationale: Fluoxetine is an inhibitor of CYP2D6.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Which of the following is an inducer of CYP3A4?

A) Quinidine
B) Methadone
C) Phenobarbital
D) Cimetidine

A

C) Phenobarbital
Rationale: Phenobarbital is an inducer of CYP3A4.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Which CYP enzyme is most crucial in drug metabolism?

A) CYP1A2
B) CYP2C9
C) CYP3A4
D) CYP2D6

A

C) CYP3A4
Rationale: CYP3A4 and CYP2D6 are the most crucial in drug metabolism, with CYP3A4 being one of the most important.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Which of the following reactions is NOT dependent on CYP450 enzymes in the liver?

A) Oxidation of dopamine
B) Hydrolysis of amides
C) Oxidation of Codeine
D) Reduction of Erythromycin

A

A) Oxidation of dopamine
Rationale: The liver carries out non-CYP450 dependent reactions, including the oxidation of dopamine.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Which substance is hydrolyzed in the liver and is NOT dependent on CYP450?

A) Lignocaine
B) Pethidine
C) Codeine
D) Nifedipine

A

A) Lignocaine
Rationale: Lignocaine undergoes hydrolysis of amides in the liver, which is a non-CYP450 dependent reaction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Which of the following is NOT an inhibitor of CYP2D6?

A) Quinidine
B) Methadone
C) Ketoconazole
D) Cimetidine

A

C) Ketoconazole
Rationale: Ketoconazole is an inhibitor of CYP3A4, not CYP2D6.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Which of the following is an inhibitor of CYP3A4?

A) Lidocaine
B) Ritonavir
C) Bufuralol
D) Desipramine

A

B) Ritonavir
Rationale: Ritonavir is an inhibitor of CYP3A4.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Which population has a prevalence of ultrarapid metabolizers between 3.4-6.5%?

A) African or Ethiopian
B) Asian
C) African American
D) Hungarian

A

C) African American
Rationale: The prevalence of ultrarapid metabolizers in the African American population is between 3.4-6.5%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Which of the following drugs is NOT a substrate of CYP2D6?

A) Bufuralol
B) Codeine
C) Nifedipine
D) Lidocaine

A

C) Nifedipine
Rationale: Nifedipine is a substrate of CYP3A4, not CYP2D6.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Which of the following is an inducer of CYP3A4?

A) Rifampin
B) Fluoxetine
C) Quinidine
D) Methadone

A

A) Rifampin
Rationale: Rifampin is an inducer of CYP3A4.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Which population has the lowest prevalence of ultrarapid metabolizers?

A) Asian
B) Greek
C) African or Ethiopian
D) Caucasian

A

A) Asian
Rationale: The prevalence of ultrarapid metabolizers in the Asian population is between 1.2-2%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Which of the following is NOT a substrate of CYP3A4?

A) Nifedipine
B) Erythromycin
C) Desipramine
D) Testosterone

A

C) Desipramine
Rationale: Desipramine is a substrate of CYP2D6, not CYP3A4.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Which of the following is a substrate of CYP2D6?

A) Lidocaine
B) Nifedipine
C) Erythromycin
D) Midazolam

A

A) Lidocaine
Rationale: Lidocaine is a substrate of CYP2D6.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Which of the following is NOT an inhibitor of CYP3A4?

A) Ketoconazole
B) Erythromycin
C) Grapefruit juice
D) Methadone

A

D) Methadone
Rationale: Methadone is an inhibitor of CYP2D6, not CYP3A4.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Which of the following is an inhibitor of CYP2D6?

A) Quinidine
B) Ritonavir
C) Phenobarbital
D) Rifampin

A

A) Quinidine
Rationale: Quinidine is an inhibitor of CYP2D6.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Which of the following is NOT an inducer of CYP3A4?

A) Carbamazepine
B) Phenobarbital
C) Quinidine
D) Phenytoin

A

C) Quinidine
Rationale: Quinidine is an inhibitor of CYP2D6, not an inducer of CYP3A4.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Which of the following reactions is dependent on CYP450 enzymes in the liver?

A) Oxidation of dopamine
B) Hydrolysis of amides
C) Oxidation of Codeine
D) Reduction of Erythromycin

A

C) Oxidation of Codeine
Rationale: Codeine is a substrate of CYP2D6, which is a CYP450 enzyme.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Which of the following is a substrate of CYP3A4?

A) Lidocaine
B) Ritonavir
C) Bufuralol
D) Midazolam

A

D) Midazolam
Rationale: Midazolam is a substrate of CYP3A4.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Which of the following is NOT an inhibitor of CYP2D6?

A) Quinidine
B) Methadone
C) Grapefruit juice
D) Cimetidine

A

C) Grapefruit juice
Rationale: Grapefruit juice is an inhibitor of CYP3A4, not CYP2D6.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Which of the following is an inhibitor of CYP3A4?

A) Lidocaine
B) Ritonavir
C) Bufuralol
D) Desipramine

A

B) Ritonavir
Rationale: Ritonavir is an inhibitor of CYP3A4.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Which population has a prevalence of ultrarapid metabolizers of 6%?

A) Asian
B) Greek
C) African or Ethiopian
D) Caucasian

A

B) Greek
Rationale: The prevalence of ultrarapid metabolizers in the Greek population is 6%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Which of the following is NOT a substrate of CYP3A4?

A) Nifedipine
B) Erythromycin
C) Desipramine
D) Testosterone

A

C) Desipramine
Rationale: Desipramine is a substrate of CYP2D6, not CYP3A4.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q
  1. Which enzyme is indicative of hepatocellular injury?
    a) ALP
    b) GGT
    c) AST
    d) Bilirubin
A

c) AST
Rationale: A rise in AST (and ALT) signals hepatocellular injury or death

ALT - Alanine transaminase
AST - Aspartase transaminase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Which condition is NOT a cause of hepatocellular injury pattern in LFTs?
a) Viral hepatitis
b) Wilson’s disease
c) Primary biliary cirrhosis
d) Alcoholic hepatitis

A

c) Primary biliary cirrhosis
Rationale: Primary biliary cirrhosis is associated with an obstructive pattern, indicated by a rise in ALP and GGT.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Which drug can cause hepatocellular injury due to toxicity?
a) Paracetamol
b) Anabolic steroids
c) Oral contraceptives
d) Antibiotics

A

a) Paracetamol
Rationale: Paracetamol toxicity can lead to hepatocellular injury, indicated by a rise in AST and ALT.

54
Q

Which enzymes suggest cholestasis in LFTs?
a) AST and ALT
b) ALP and GGT
c) Bilirubin and Albumin
d) None of the above

A

b) ALP and GGT
Rationale: A rise predominantly in ALP and GGT suggests cholestasis, indicating an obstructive pattern.

55
Q

Which of the following is NOT a cause of an obstructive pattern in LFTs?
a) Primary biliary cirrhosis
b) Alcoholic hepatitis
c) Obstruction due to calculi
d) Tumors

A

b) Alcoholic hepatitis
Rationale: Alcoholic hepatitis is associated with hepatocellular injury, not an obstructive pattern.

56
Q

The SARS-CoV-2 virus uses which receptor to enter cells?
a) ACE-1
b) ACE-2
c) GGT
d) ALP

A

b) ACE-2
Rationale: The SARS-CoV-2 virus uses angiotensin-converting enzyme 2 (ACE-2) receptors to gain entry into cells.

57
Q

Which region of the liver has an abundance of ACE-2 receptors?
a) Hepatocellular region
b) Canalicular region
c) Ducal region
d) Lobular region

A

c) Ducal region
Rationale: The ducal region of the liver has an abundance of ACE-2 receptors, making it susceptible to SARS-CoV-2.

58
Q

What percentage of COVID-19 patients may present with hepatic decompensation without respiratory symptoms, as suggested by an international registry?
a) 10%
b) 25%
c) 50%
d) 75%

A

b) 25%
Rationale: An international registry has suggested that as many as 25% of patients with COVID-19 may present with hepatic decompensation in the absence of respiratory symptoms.

59
Q

Which of the following is NOT a pharmacokinetic effect of liver disease?
a) Altered absorption
b) Increased volume of distribution
c) Enhanced protein synthesis
d) Reduced protein synthesis

A

c) Enhanced protein synthesis
Rationale: Liver disease can lead to reduced protein synthesis, not enhanced.

60
Q

Which protein’s synthesis may be reduced in liver disease, affecting drug binding and pharmacokinetics?
a) Hemoglobin
b) Fibrinogen
c) Albumin
d) Globulin

A

c) Albumin
Rationale: Albumin synthesis may be reduced in liver disease, affecting drug binding, volume of distribution, half-life, and action duration.

61
Q

Which condition can cause an isolated rise in unconjugated bilirubin?
a) Alcoholic hepatitis
b) Gilbert’s syndrome
c) Primary biliary cirrhosis
d) Viral hepatitis

A

b) Gilbert’s syndrome
Rationale: An isolated rise in unconjugated bilirubin can be attributed to Gilbert’s syndrome.

62
Q

Which of the following can cause a mixed pattern in LFTs?
a) Sepsis
b) Wilson’s disease
c) Paracetamol toxicity
d) Primary biliary cirrhosis

A

a) Sepsis
Rationale: A mixed pattern can be seen in conditions like sepsis, some drug reactions, cholangitis, and others.

63
Q

Which drug can cause raised liver enzyme assays, raised bilirubin, and jaundice?
a) Paracetamol
b) Anabolic steroids
c) Halothane
d) Oral contraceptives

A

c) Halothane
Rationale: Halothane hepatitis can cause raised liver enzyme assays, raised bilirubin, and jaundice.

64
Q

Which of the following is NOT a cause of hepatocellular injury?
a) Ischaemic hepatitis
b) Autoimmune hepatitis
c) Cholangitis
d) Viral hepatitis

A

c) Cholangitis
Rationale: Cholangitis can cause a mixed pattern in LFTs, not specifically hepatocellular injury.

65
Q

In liver failure, the absorption of drugs given orally or nasogastrically can be affected by:
a) Increased gastric emptying
b) Reduced gastric transit time
c) Splanchnic vasodilation
d) Delayed gastric emptying

A

d) Delayed gastric emptying
Rationale: The absorption of drugs can be affected by delayed gastric emptying or reduced absorption due to diarrhea and increased gastric transit time seen in liver failure.

66
Q

Which of the following drugs is NOT associated with an obstructive pattern in LFTs?
a) Anabolic steroids
b) Oral contraceptives
c) Paracetamol
d) Antibiotics

A

c) Paracetamol
Rationale: Paracetamol is associated with hepatocellular injury, not an obstructive pattern.

67
Q

Which of the following conditions is associated with a rise in AST and ALT?
a) Hepatocellular injury
b) Cholestasis
c) Hemolysis
d) Gilbert’s syndrome

A

a) Hepatocellular injury
Rationale: A rise in AST and ALT signals hepatocellular injury or death.

68
Q

Which of the following is NOT a cause of a mixed pattern in LFTs?
a) Sepsis
b) Cholangitis
c) Wilson’s disease
d) Alcoholic liver disease

A

c) Wilson’s disease
Rationale: Wilson’s disease causes hepatocellular injury, not a mixed pattern.

69
Q

Which of the following conditions can cause fluid retention, affecting the volume of drug distribution?
a) Hepatic dysfunction
b) Renal dysfunction
c) Cardiac dysfunction
d) Pulmonary dysfunction

A

a) Hepatic dysfunction
Rationale: Hepatic dysfunction can cause fluid retention, increasing the volume within which drugs are present.

70
Q
  1. Which of the following drugs can cause hepatocellular injury due to toxicity?
    a) Paracetamol
    b) Halothane
    c) Both a and b
    d) Neither a nor b
A

c) Both a and b
Rationale: Both paracetamol and halothane can cause hepatocellular injury due to toxicity.

71
Q
  1. Which enzyme is NOT indicative of cholestasis?
    a) ALP
    b) GGT
    c) AST
    d) Bilirubin
A

c) AST
Rationale: ALP and GGT are indicative of cholestasis, while AST indicates hepatocellular injury.

72
Q
  1. Which of the following conditions can cause an isolated rise in unconjugated bilirubin?
    a) Hemolysis
    b) Alcoholic hepatitis
    c) Cholangitis
    d) Viral hepatitis
A

a) Hemolysis
Rationale: An isolated rise in unconjugated bilirubin can be attributed to hemolysis.

73
Q
  1. Which of the following is NOT a pharmacokinetic effect of liver disease?
    a) Altered absorption
    b) Increased volume of distribution
    c) Enhanced protein synthesis
    d) Reduced protein synthesis
A

c) Enhanced protein synthesis
Rationale: Liver disease can lead to reduced protein synthesis, not enhanced.

74
Q

Which protein’s synthesis may be reduced in liver disease, affecting drug binding and pharmacokinetics?
a) Hemoglobin
b) Fibrinogen
c) Albumin
d) Globulin

A

c) Albumin
Rationale: Albumin synthesis may be reduced in liver disease, affecting drug binding, volume of distribution, half-life, and action duration.

75
Q
  1. Which of the following conditions is associated with a rise in AST and ALT?
    a) Hepatocellular injury
    b) Cholestasis
    c) Hemolysis
    d) Gilbert’s syndrome
A

a) Hepatocellular injury
Rationale: A rise in AST and ALT signals hepatocellular injury or death.

76
Q

Which of the following is NOT a cause of a mixed pattern in LFTs?
a) Sepsis
b) Cholangitis
c) Wilson’s disease
d) Alcoholic liver disease

A

c) Wilson’s disease
Rationale: Wilson’s disease causes hepatocellular injury, not a mixed pattern.

77
Q

Which of the following conditions can cause fluid retention, affecting the volume of drug distribution?
a) Hepatic dysfunction
b) Renal dysfunction
c) Cardiac dysfunction
d) Pulmonary dysfunction

A

a) Hepatic dysfunction
Rationale: Hepatic dysfunction can cause fluid retention, increasing the volume within which drugs are present.

78
Q

Which of the following drugs can cause hepatocellular injury due to toxicity?
a) Paracetamol
b) Halothane
c) Both a and b
d) Neither a nor b

A

c) Both a and b
Rationale: Both paracetamol and halothane can cause hepatocellular injury due to toxicity.

79
Q

Which enzyme is NOT indicative of cholestasis?
a) ALP
b) GGT
c) AST
d) Bilirubin

A

c) AST
Rationale: ALP and GGT are indicative of cholestasis, while AST indicates hepatocellular injury.

80
Q

Which of the following conditions can cause an isolated rise in unconjugated bilirubin?
a) Hemolysis
b) Alcoholic hepatitis
c) Cholangitis
d) Viral hepatitis

A

a) Hemolysis
Rationale: An isolated rise in unconjugated bilirubin can be attributed to hemolysis.

81
Q
  1. Which of the following is a late consequence of portal hypertension in cirrhosis?
    A) Hepatic encephalopathy
    B) Ascites
    C) Hyperdynamic syndrome
    D) Hepatorenal syndrome
A

C) Hyperdynamic syndrome
Rationale: The hyperdynamic syndrome is a late consequence of portal hypertension in cirrhosis, characterized by high cardiac output, increased heart rate, and increased total blood volume.

82
Q

. In liver failure, what happens to the drug’s extraction ratio?
A) Increases
B) Decreases
C) Remains the same
D) Doubles

A

B) Decreases
Rationale: In liver failure, the degree of metabolism is reduced, leading to a decreased extraction ratio.

83
Q
  1. Which drug has been implicated in causing hepatitis?
    A) Sevoflurane
    B) Isoflurane
    C) Halothane
    D) Desflurane
A

C) Halothane
Rationale: Halothane has been associated with causing hepatitis, especially in the context of oxidative metabolism in the liver.

84
Q
  1. What percentage of critically ill patients have hepatic dysfunction?
    A) 5-10%
    B) 11-54%
    C) 55-70%
    D) 71-85%
A

B) 11-54%
Rationale: 11-54% of critically ill patients are reported to have hepatic dysfunction.

85
Q
  1. What is the extraction ratio (ER) of a drug?
    A) The fraction of drug metabolized in the liver
    B) The fraction of drug excreted in the urine
    C) The fraction of drug that is removed from the blood as it crosses the eliminating organ
    D) The fraction of drug bound to plasma proteins
A

C) The fraction of drug that is removed from the blood as it crosses the eliminating organ
Rationale: ER represents the fraction of a drug removed from the blood or plasma as it passes through an eliminating organ like the liver or kidney.

86
Q
  1. Which type of hepatitis caused by Halothane is characterized by fever, jaundice, and elevated serum transaminases?
    A) Type 1
    B) Type 2
    C) Type 3
    D) Type 4
A

B) Type 2
Rationale: Type 2 hepatitis caused by Halothane is characterized by oxidative metabolism of halothane in the liver leading to symptoms like fever, jaundice, and elevated serum transaminases.

87
Q
  1. In cirrhosis, what happens to first-pass metabolism?
    A) Increases
    B) Decreases
    C) Remains the same
    D) Doubles
A

B) Decreases
Rationale: First-pass metabolism is decreased in cirrhosis, leading to increased bioavailability of drugs.

88
Q
  1. Which of the following drugs has its clearance dependent on blood flow?
    A) Drugs with high extraction ratios
    B) Drugs with low extraction ratios
    C) Both
    D) Neither
A

A) Drugs with high extraction ratios
Rationale: Drugs with high extraction ratios have their clearance dependent on blood flow.

89
Q
  1. What is the main effect of vasopressors on liver blood flow?
    A) Increase
    B) Decrease
    C) No effect
    D) Variable effect
A

B) Decrease
Rationale: Vasopressors reduce liver blood flow, which can further reduce the extraction ratios of drugs.

90
Q
  1. Which of the following is NOT a manifestation of the hyperdynamic syndrome?
    A) High cardiac output
    B) Increased heart rate
    C) Reduced total systemic vascular resistance
    D) Reduced cardiac output
A

D) Reduced cardiac output
Rationale: The hyperdynamic syndrome is characterized by high cardiac output, not reduced.

91
Q
  1. Which inhalational agent is associated with the generation of trifluoroacetyl chloride (TFA)?
    A) Sevoflurane
    B) Isoflurane
    C) Halothane
    D) Desflurane
A

C) Halothane
Rationale: Halothane undergoes oxidative metabolism leading to the generation of trifluoroacetyl chloride (TFA).

92
Q

Which type of hepatitis caused by Halothane is mild and transient?
A) Type 1
B) Type 2
C) Type 3
D) Type 4

A

A) Type 1
Rationale: Type 1 hepatitis caused by Halothane is mild, transient, and has a relatively high incidence.

93
Q
  1. What effect can IV anesthetics have on blood pressure?
    A) Gradual increase
    B) Gradual decrease
    C) Sudden precipitous fall
    D) No effect
A

C) Sudden precipitous fall
Rationale: IV anesthetics can cause a sudden and sharp drop in blood pressure.

94
Q
  1. In liver failure, what happens to the bioavailability of drugs?
    A) Increases
    B) Decreases
    C) Remains the same
    D) Variable effect
A

A) Increases
Rationale: In liver failure, more drug reaches the systemic circulation due to a decreased extraction ratio, thus increasing bioavailability.

95
Q
  1. What is the main consequence of reduced first-pass metabolism in cirrhosis?
    A) Reduced drug effect
    B) Increased drug effect
    C) No change in drug effect
    D) Variable drug effect
A

B) Increased drug effect
Rationale: Reduced first-pass metabolism in cirrhosis leads to increased bioavailability of drugs, potentially increasing their effect.

96
Q
  1. Which of the following drugs has its clearance limited by reduced metabolism, not blood flow?
    A) Drugs with high extraction ratios
    B) Drugs with low extraction ratios
    C) Both
    D) Neither
A

B) Drugs with low extraction ratios
Rationale: Drugs with low extraction ratios have their clearance limited by metabolism, not by blood flow.

97
Q
  1. Which of the following is a consequence of the oxidative metabolism of Halothane in the liver?
    A) Generation of trifluoroacetyl chloride (TFA)
    B) Reduced first-pass metabolism
    C) Increased extraction ratio
    D) Reduced bioavailability
A

A) Generation of trifluoroacetyl chloride (TFA)
Rationale: Oxidative metabolism of Halothane in the liver leads to the generation of trifluoroacetyl chloride (TFA).

98
Q
  1. Which of the following is NOT a characteristic of the hyperdynamic syndrome?
    A) Reduced heart rate
    B) High cardiac output
    C) Increased total blood volume
    D) Reduced total systemic vascular resistance
A

A) Reduced heart rate
Rationale: The hyperdynamic syndrome is characterized by an increased heart rate, not a reduced one.

99
Q
  1. In the context of drug metabolism, what is the role of the liver?
    A) Excretion
    B) Absorption
    C) Metabolism
    D) Distribution
A

C) Metabolism
Rationale: The liver plays a crucial role in the metabolism of drugs, converting them into metabolites.

100
Q
  1. Which of the following is a potential effect of drugs with high extraction ratios in the presence of reduced liver blood flow?
    A) Increased clearance
    B) Decreased clearance
    C) No change in clearance
    D) Variable effect on clearance
A

B) Decreased clearance
Rationale: Drugs with high extraction ratios have their clearance dependent on blood flow. Reduced liver blood flow can lead to decreased clearance of these drugs.

101
Q
  1. Which of the following is an active metabolite of morphine?
    a) Codeine
    b) Fentanyl
    c) Morphine-6-glucuronide
    d) Alfentanil
A

c) Morphine-6-glucuronide

Rationale: Morphine is metabolized in the liver to produce active metabolites, namely morphine-6-glucuronide and morphine-3-glucuronide.

102
Q

In liver failure, what happens to the extraction ratio of morphine?
a) Increases
b) Decreases
c) Remains the same
d) Doubles

A

b) Decreases

Rationale: In the event of liver failure, the extraction ratio of morphine is reduced, leading to an accumulation of morphine in the body.

103
Q
  1. Codeine is converted to which substance in the liver?
    a) Fentanyl
    b) Alfentanil
    c) Morphine
    d) NSAID
A

c) Morphine

Rationale: Codeine is converted to morphine in the liver by the CYP2D6 enzyme.

104
Q
  1. Which enzyme is responsible for the conversion of codeine to morphine?
    a) CYP3A4
    b) CYP2D6
    c) CYP1A2
    d) CYP2C9
A

b) CYP2D6

Rationale: Codeine is converted to morphine in the liver by the CYP2D6 enzyme.

105
Q
  1. In patients with liver disease, what happens to the bioavailability of NSAIDs?
    a) Increases
    b) Decreases
    c) Remains the same
    d) Is halved
A

a) Increases

Rationale: In patients with liver disease, there’s an increased bioavailability of NSAIDs.

106
Q
  1. Which of the following is NOT a substitute for NSAIDs in patients with liver disease?
    a) Pregabalin
    b) Gabapentin
    c) Paracetamol
    d) Morphine
A

d) Morphine

Rationale: Pregabalin and gabapentin can be used as alternatives to NSAIDs in patients with liver disease. Morphine is an opioid analgesic and not a direct substitute for NSAIDs.

107
Q
  1. How much paracetamol can lead to hepatocellular necrosis?
    a) 1.5g
    b) 3.5g
    c) 5.5g
    d) 7.5g
A

d) 7.5g

Rationale: Ingesting as little as 7.5g of paracetamol can lead to hepatocellular necrosis.

108
Q
  1. Which of the following is NOT a symptom of severe paracetamol poisoning?
    a) Nausea
    b) Hypoglycaemia
    c) Hypertension
    d) Metabolic acidosis
A

c) Hypertension

Rationale: Indicators of severe paracetamol poisoning include nausea, hypoglycaemia, and metabolic acidosis. Hypertension is not a direct symptom of paracetamol poisoning.

109
Q
  1. Which drug, when used for COVID-19, can lead to elevated liver enzymes?
    a) Remdesivir
    b) Tocilizumab
    c) Dexamethasone
    d) Paracetamol
A

a) Remdesivir

Rationale: Clinical trials have observed elevated liver enzymes in patients treated with remdesivir.

110
Q
  1. Which of the following steroids may reactivate HBV in high doses?
    a) Dexamethasone
    b) Prednisolone
    c) Methylprednisolone
    d) Hydrocortisone
A

c) Methylprednisolone

Rationale: Use of methylprednisolone in high doses might reactivate HBV.

111
Q
  1. Which of the following is NOT to be avoided in liver disease?
    a) Abacavir
    b) COX-2 inhibitors
    c) Sertraline
    d) Aspirin
    e) AOTA
A

e) AOTA
Acetaminophen, COX 2 inh, NSAID (aspirin)

112
Q
  1. Which opioid is contraindicated in breastfeeding mothers?
    a) Morphine
    b) Fentanyl
    c) Codeine
    d) Alfentanil
A

c) Codeine

Rationale: Breastfeeding mothers should avoid codeine as it can be passed to the infant through breast milk, potentially causing harm.

113
Q
  1. Which of the following is NOT an effect of NSAIDs in liver disease?
    a) Increased bioavailability
    b) Reduced risk of GI bleeding
    c) Risk of renal failure
    d) Potential hepatotoxicity
A

b) Reduced risk of GI bleeding

Rationale: In patients with liver disease, there’s an increased bioavailability of NSAIDs and a higher risk of GI bleeding.

114
Q
  1. Which enzyme is elevated in patients treated with Remdesivir?
    a) Amylase
    b) Lipase
    c) ALT
    d) AST
A

c) ALT

Rationale: Clinical trials have observed elevated ALT levels in patients treated with remdesivir.

115
Q
  1. Which drug used in COVID-19 therapy can lead to ALT elevations but rarely causes fulminant hepatitis?
    a) Dexamethasone
    b) Tocilizumab
    c) Remdesivir
    d) Hydroxychloroquine
A

b) Tocilizumab

Rationale: While ALT elevations are common with Tocilizumab, fulminant hepatitis is rare.

116
Q
  1. In patients with chronic liver disease, what is the recommended daily dosage of paracetamol?
    a) 1-2 g/day
    b) 2-3 g/day
    c) 3-4 g/day
    d) 4-5 g/day
A

b) 2-3 g/day

Rationale: For patients with chronic liver disease, the recommended daily dosage of paracetamol as an analgesic is reduced to 2-3 g/day.

117
Q
  1. Which of the following is NOT a symptom of severe paracetamol poisoning?
    a) Encephalopathy
    b) Hypoglycaemia
    c) Diarrhea
    d) Hypotension
A

c) Diarrhea

Rationale: Diarrhea is not a direct symptom of paracetamol poisoning. Other symptoms like encephalopathy, hypoglycaemia, and hypotension are indicators of severe poisoning.

118
Q
  1. Which of the following drugs can reactivate HBV when used in high doses?
    a) Dexamethasone
    b) Methylprednisolone
    c) Tocilizumab
    d) Remdesivir
A

b) Methylprednisolone

Rationale: Use of methylprednisolone in high doses might reactivate HBV.

119
Q
  1. Which of the following is NOT an opioid?
    a) Codeine
    b) Fentanyl
    c) Pregabalin
    d) Morphine
A

c) Pregabalin

Rationale: Pregabalin is an anticonvulsant and neuropathic pain agent, not an opioid.

120
Q
  1. Which of the following drugs is contraindicated in CYP2D6 ultra-rapid metabolizers?
    a) Morphine
    b) Fentanyl
    c) Codeine
    d) Alfentanil
A

c) Codeine

Rationale: Codeine is contraindicated in individuals known to be CYP2D6 ultra-rapid metabolizers due to the risk of rapid conversion to morphine.

121
Q
  1. Which of the following is a potential side effect of NSAIDs in liver disease?
    a) Decreased bioavailability
    b) Reduced risk of renal failure
    c) Increased risk of GI bleeding
    d) Reduced risk of hepatotoxicity
A

c) Increased risk of GI bleeding

Rationale: In patients with liver disease, there’s a higher risk of GI bleeding due to NSAIDs.

122
Q
  1. Which of the following drugs, when used for COVID-19, can lead to elevated liver enzymes but rarely requires treatment discontinuation?
    a) Dexamethasone
    b) Tocilizumab
    c) Remdesivir
    d) Hydroxychloroquine
A

c) Remdesivir

Rationale: Clinical trials have observed elevated liver enzymes in patients treated with remdesivir, but these elevated values rarely necessitate discontinuation of the drug.

123
Q
  1. Which of the following is NOT a treatment option for fulminant liver failure due to paracetamol overdose?
    a) Liver transplantation
    b) N-acetylcysteine
    c) Dialysis
    d) High-dose vitamin C
A

d) High-dose vitamin C

Rationale: Liver transplantation and N-acetylcysteine are treatment options for fulminant liver failure due to paracetamol overdose. High-dose vitamin C is not a standard treatment for this condition.

124
Q
  1. Which of the following drugs can lead to ALT elevations and has a risk of reactivating HBV in patients with viral etiology liver disease?
    a) Dexamethasone
    b) Tocilizumab
    c) Remdesivir
    d) Hydroxychloroquine
A

b) Tocilizumab

Rationale: Tocilizumab can lead to ALT elevations, and there’s a risk of HBV reactivation if the patient has chronic liver disease due to viral etiology.

125
Q
  1. Which of the following drugs is probably safe in low doses for patients with chronic stable liver disease?
    a) Dexamethasone
    b) Methylprednisolone
    c) Tocilizumab
    d) Remdesivir
A

a) Dexamethasone

Rationale: Low-dose dexamethasone is likely safe for patients with stable chronic liver disease.

126
Q
  1. Which of the following is NOT an opioid?
    a) Codeine
    b) Gabapentin
    c) Morphine
    d) Fentanyl
A

b) Gabapentin

Rationale: Gabapentin is an anticonvulsant and neuropathic pain agent, not an opioid.

127
Q
  1. Which of the following drugs can increase the risk of spontaneous bacterial peritonitis (SBP) in severe cases?
    a) Dexamethasone
    b) Methylprednisolone
    c) Tocilizumab
    d) Remdesivir
A

b) Methylprednisolone

Rationale: Use of methylprednisolone in high doses may increase the risk of spontaneous bacterial peritonitis (SBP) in severe cases.

128
Q
  1. Which of the following is NOT to be avoided in liver disease?
    a) Green tea extract
    b) COX-2 inhibitors
    c) Tacrolimus
    d) Metformin
A

d) Metformin

Rationale: Green tea extract, COX-2 inhibitors, and tacrolimus are among the medications that can have adverse effects on the liver or exacerbate existing liver conditions. Metformin, while used for diabetes, is not specifically listed among the medications to avoid in the provided list.

129
Q
  1. Which of the following drugs, when used for COVID-19, can lead to ALT elevations but rarely causes fulminant hepatitis?
    a) Dexamethasone
    b) Tocilizumab
    c) Remdesivir
    d) Hydroxychloroquine
A

b) Tocilizumab

Rationale: While ALT elevations are common with Tocilizumab, fulminant hepatitis is rare.

130
Q
  1. Which of the following is a potential side effect of NSAIDs in liver disease?
    a) Decreased bioavailability
    b) Reduced risk of renal failure
    c) Increased risk of GI bleeding
    d) Reduced risk of hepatotoxicity
A

c) Increased risk of GI bleeding

Rationale: In patients with liver disease, there’s a higher risk of GI bleeding due to NSAIDs.